Abbott Laboratories (NYSE: ABT) operates in four segments: pharmaceutical products, diagnostic products, nutritional products, and vascular products.
The Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for the treatment of dyslipidemia, cholesterol, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hypothyroidism, obesity, HIV infection, epilepsy and bipolar disorder, migraines, hyperparathyroidism, endometriosis and central precocious puberty, anemia, duodenal ulcers, gastric ulcers, erosive esophagitis, and hypertension.
The Diagnostic Products segment provides diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician's offices, alternate-care testing sites, plasma protein therapeutic companies, and consumers. Products include immunoassay systems, chemistry systems, assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases, such as hepatitis and HIV, genomic-based tests, hematology systems and reagents, blood glucose monitoring meters, test strips, data management software, and accessories for people with diabetes, and point-of-care diagnostic systems and tests for blood analysis.
The Nutritional Products segment offers pediatric and adult nutritionals.
The Vascular Products segment provides a line of coronary, endovascular, and vessel closure devices for the treatment of vascular diseases.
Some deals and collaborations include:
- A 50% owned joint venture with TAP Pharmaceuticals
- A strategic alliance with Celera Diagnostics
- A collaboration with Genentech (NYSE: DNA) to develop anti-cancer compounds
